Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus rhamnosus 19070-2
- Development stage
- Unknown
- Lead developer
- Biocare Copenhagen
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus rhamnosus 19070-2 is a specific probiotic bacterial strain used as a dietary supplement, primarily for gut health and the management of gastrointestinal conditions such as infant colic. It is part of the species Lactobacillus (now reclassified as Lacticaseibacillus) rhamnosus, which are lactic acid bacteria naturally found in the human gut and various fermented foods. This strain has been studied in combination with other probiotics for its ability to reduce crying and fussing in infants with colic, likely by modulating intestinal microbiota and supporting gut barrier function[1][5][7]. The mechanism involves competitive inhibition of pathogenic bacteria, enhancement of mucosal barrier integrity, modulation of immune responses, and production of beneficial metabolites such as lactic acid[8]. It is not classified or approved as a pharmaceutical drug but is marketed as a probiotic dietary supplement.
- Brand names
- FloraActive
- Other names
- Lacticaseibacillus rhamnosus 19070-2L. rhamnosus 19070-2
Beyond the preview
Go deeper on lactobacillus rhamnosus 19070-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus rhamnosus 19070-2.